Herzmann, Christian

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 568

Evaluation of Galactomannan Testing, the Aspergillus-Specific Lateral-Flow Device Test and Levels of Cytokines in Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis

Salzer, H. J. F., Prattes, J., Flick, H., Reimann, M., Heyckendorf, J., Kalsdorf, B., Obersteiner, S., Gaede, K. I., Herzmann, C., Johnson, G. L., et al. (2018) · Frontiers in Microbiology

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 41